IMAC Holdings, Inc. announced it has completed the third cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson's disease. The third cohort consists of five patients with bradykinesia due to Parkinson's disease receiving an intravenous infusion of a high concentration stem cell treatment. The third and final cohort of the Phase 1 clinical trial was completed on Tuesday, September 6, 2022.

About IMAC's Phase 1 Clinical Trial: The Phase 1 clinical trial, consisting of a 15-patient dose escalation safety and tolerability study, is being conducted at three of IMAC's clinical centers in Chesterfield, Missouri, Paducah, Kentucky, and Brentwood, Tennessee. The trial is divided into three groups: five patients with bradykinesia due to Parkinson's disease received a low concentration dose, intravenous infusion of stem cells, five received a medium concentration intravenous dose, and five received a high concentration intravenous dose. All groups will be subsequently tracked for 12 months.

IMAC's medical doctors and physical therapists at the clinical sites have been trained to administer the treatment and manage the therapy. Ricardo Knight, M.D., M.B.A., who is medical director of the IMAC Regeneration Center of Chicago, is the trial's principal investigator. The Institute of Regenerative and Cellular Medicine serves as the trial's independent investigational review board, while Regenerative Outcomes provides management of the study.